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SIR,  
Methylisothiazolinone (MI) is a preservative used in many household and industrial products. 
There has been an unprecedented global rise in allergic contact dermatitis (ACD) from its 
presence in personal care products (PCPs). 
In 2005 changes to EU legislation allowed MI, used in combination with 
methylchloroisothiazolinone (MCI), to be used at concentrations of up to 100ppm, 25 times 
higher than previously permitted. MI was also permitted to be used alone, whereas previously 
it was only used in combination with MCI in a 3:1 mix.1This resulted in the chain of events 
that led to the current MI allergy epidemic.By 2010, the first case series of ACD to MI as a 
cosmetic allergen was published.2One year later in 2011 MI was included in the British 
standard series and European minimal baseline series3 and by 2013 it was dubbed ‘Contact 
Allergen of the year’ by the American Contact Dermatitis Society!4 
In 2014 the British Society for Cutaneous Allergy described an epidemic of ACD to MI with 
over 1% of the UK population estimated to be affected.  We reported an increase in ACD to 
MI from 1.7% of those patch tested in 2010 to 11.1% in 2013.5 We have continued to collect 
data to provide evidence to governing bodies on sensitization to  MI in PCPs and to inform 
discussion with the cosmetics industry.  
 
From January 1st to June 30th 2014 was collected from 13 centres across the UK and Ireland. 
Numbers of patients tested to MI, MCI/MI and their results were analysed and compared with 
the previously collected results from 17 centres from January 2010 to December 2013. In all 
centres, test agents were applied in Finn Chambers® according to International Contact 
Dermatitis Research Group guidelines with readings performed on day two and day four. 
In total, 3897 patients were patch tested to MI and 2708 patients were patch tested to MCI/MI 
from January 1st to June 30th 2014.  Of these, all were tested to MI 0.2% in aqueous form 
(aq), (Chemotechnique Diagnostics, Vellinge, Sweden) and MCI/MI 0.01% (aq) or 0.02% 
(aq) (Trolab, Reinbeck, Germany).  
 
A summary of our data from 2010 to 2014 is shown in table 1 and figure 1a-c. Whilst we had 
previously reported a steadily increasing incidence of ACD to MI of around 3% per year 
from 2010 to 2013, in 2014 it appears to have reduced for the first time since we started 
recording by -0.30%.  Although the overall incidence of ACD to MI may have reached a 
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plateau, it still remains very high, affecting a mean of 10.73% of the patch test clinic 
population. The incidence of allergy to MCI/MI appears to have mirrored this plateau effect 
with it reaching 9.60% in 2014 but still yet to decline. 
Interestingly, there remains a wide range in the incidence of ACD, figures 1b-c. However 7 
centres report a decline in incidence of ACD to MI 2014. Similarly, data for ACD to MCI/MI 
is varied but does show a trend toward a stabilisation of incidence in 2014, with 6 centres 
reporting a decline. 
Global clinical data on contact sensitization and ACD have established that the current use of 
MI at 100ppm in PCPs is unsafe, and this should not be disregarded especially when risk 
assessment based on predictive assays has failed. 
Potential reasons for this apparent plateau are twofold: firstly, there is increased awareness of 
MI allergy amongst the general public due to media coverage, and secondly the cosmetics 
industry has started to reformulate ‘leave on’ PCPs which have been filtering into shops over 
the past 18 months. Whether this has resulted from pressure from the media or the 
dermatology community remains to be seen. 
Although the rate of increase of incidence of allergy to MI in our clinics may be starting to 
plateau, overall prevalence in the UK is still rising. Slow government and industry response 
to increasing pressure from clinicians allowed the incidence of ACD to MI to reach 11.03% 
in 2013 with a current incidence of new allergy diagnosed in 10.73% of those patch tested 
shows that the MI epidemic is far from resolved. Therefore it is important that dermatologists 
continue to apply pressure on commercial and governing bodies to ensure that MI is further 
restricted.   
In July 2015 new EU legislation restricted the concentrations of MCI/MI in rinse off products 
to 15ppm, and banned MI in combination with MCI from leave on products. Similar 
restrictions are due to come into place for MI use alone.6 
Completely restricting MI would result in a gradual decline in sensitization as previously 
seen with methyldibromoglutaronitrile (MDBGN). However, unlike MDBGN, MI has not yet 
been banned outright and so this trend cannot be predicted. The incidence of ACD to MI is 
only likely to decline if further changes to legislation are made. 
With the European cosmetics industry permitted to use MI alone at a concentration in “rinse 
off” PCPs at 100ppm, and data suggesting that MI will elicit reactions in MI sensitized 
individuals at concentrations of 50ppm in rinse off products,7 a large proportion of the 
undiagnosed public will suffer from continued episodes of ACD. 
Another challenge remains in the use of MI in non-cosmetic products where there is not 
currently an equivalent legal requirement to report the presence of MI on product labelling, or 
any restriction on the concentration. Studies have already identified that airborne exposure to 
paints with MI can trigger ACD in those already sensitised, as well as those with no history 
of allergy to MI.8,9 Of note, in some European countries it is required to report the presence 
of biocides in non-cosmetic products when the concentration exceeds 1%. 
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In 1997, Alan Dillarstone predicted the regular development of new preservative allergies.10 
This has been reflected clinically where a new wave of sensitization develops as one allergen 
is phased out and replaced with another. While the current epidemic of sensitization to MI is 
not over, we must remain vigilant to new cosmetic allergens arising. 
 
In summary, the incidence of ACD to MI in the UK shows a decline for the first time, 
reaching a peak of 11.03% for ACD to MI and in 2013 and falling to 10.73% in 2014. Further 
action is needed to accelerate this decline 
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Table 1: Number of patients tested with, and number of patients with a positive patch test reaction 
to, methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI) and MI in participating centres 
from January 2010 to June 2014 
Year Patients 
tested to 
MCI/MI 
Patient 
positive to 
MCI/MI 
% Positive Patients 
tested to MI 
Patients 
positive to 
MI 
% Positive
2010 3185 130 4.08 2279 38 1.67 
2011 4368 220 5.04 2543 125 4.92 
2012 4612 275 5.95 4984 383 7.68 
2013 3346 303 9.06 3936 434 11.03 
2014* 2708 260 9.60 3897 418 10.73 
 
* Data collected from Jan 1st to June 30th 2014. 
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